Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20987564 | 0.90 | RNASE1 (0.32) | RNASE1TOP2APOLBTUBB1 | |
| SCHEMBL17230899 | 0.86 | RNASE1 (0.38) | RNASE1SLC6A2 | |
| SCHEMBL17230947 | 0.84 | RNASE1 (0.38) | RNASE1SLC6A2 | |
| SCHEMBL21078848 | 0.77 | KMT2A (0.33) | RNASE1KMT2ATDP1ALDH1A1 | |
| SCHEMBL17231038 | 0.77 | RNASE1 (0.38) | RNASE1SLC6A2 | |
| SCHEMBL20987567 | 0.76 | POLB (0.35) | TOP2APOLBTUBB1 | |
| SCHEMBL29897125 | 0.74 | RNASE1 (0.68) | RNASE1POLB | |
| SCHEMBL29319148 | 0.74 | RNASE1 (0.60) | RNASE1SLC6A2TOP2A | |
| SCHEMBL23914022 | 0.73 | RNASE1 (0.57) | RNASE1SLC6A2TOP2A | |
| SCHEMBL767324 | 0.73 | RNASE1 (0.68) | RNASE1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | RNGTT, POLR2H, POLR2E | RNASE1 104/4885SLC6A2 3459/4885KMT2A 1642/4885 |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | RNASE1 97/4885SLC6A2 3222/4885KMT2A 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.